ASSURE Wearable ECG vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
ASSURE Wearable ECG
by Kestra Medical Technologies
VS
ElucidVivo A.3
by Elucid

AI Verdict

These two tools are adjacent rather than direct competitors, as they address distinct aspects of cardiac care. ASSURE Wearable ECG focuses on continuous heart rate monitoring and ECG data collection for detecting cardiac events, while ElucidVivo A.3 specializes in AI-powered quantitative analysis of arterial plaque from CT angiography to aid in atherosclerosis patient stratification. A clinician would choose between them based on whether they need real-time rhythm monitoring or detailed structural analysis of arterial disease.

Choose ASSURE Wearable ECG if…

Choose ASSURE Wearable ECG if you need continuous, real-time heart rate monitoring and event detection for at-risk cardiac patients in an outpatient setting. This tool is ideal for remotely managing patients with suspected arrhythmias or those requiring ongoing surveillance for cardiac events, providing clinicians with alert-based notifications and physiologic trend data.

View ASSURE Wearable ECG →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography scans. This system is best suited for stratifying atherosclerosis patients and optimizing treatment decisions by providing detailed visualization and measurement of plaque characteristics, validated against histology.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature ASSURE Wearable ECG ElucidVivo A.3
Pricing Contact for pricing. Unknown
Deployment Wearable device, mobile application, and cloud-based remote patient data platform. Cloud and on-premise secure deployment.
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ASSURE Wearable ECG

Tool A emphasizes patient comfort and intuitive design with its SensorFit Garment and mobile application, which includes troubleshooting and educational resources for patients. This focus on patient-centric usability for a wearable device provides a clear advantage.

Clinical Value

ElucidVivo A.3

Tool B offers advanced diagnostic insights through AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography, validated against histology, and the derivation of FFRct. This provides a deeper, more predictive clinical impact on patient stratification and treatment optimization for atherosclerosis.

Pricing & Value

Tie

Both tools explicitly state 'contact for pricing,' making it impossible to compare their pricing structures or assess their value proposition without specific cost information. While Tool A's company has undergone an IPO, this does not translate to transparent pricing for end-users.

Enterprise Readiness

ASSURE Wearable ECG

Tool A explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption and data security in healthcare. While Tool B is FDA cleared and integrates with PACS/EMR, it does not explicitly confirm BAA availability in the provided information.

Innovation

ElucidVivo A.3

Tool B demonstrates a higher level of innovation by providing AI-powered quantitative analysis of arterial plaque composition and stability from CT images, validated against ground-truth histology, and deriving FFRct. This capability, offering 'CT Virtual Histologyu2122,' represents a significant advancement in non-invasive cardiovascular diagnostics.

Support & Docs

ASSURE Wearable ECG

Tool A provides a dedicated ASSURE Helpline, and its patient app offers troubleshooting information and educational videos, along with patient handbooks and user manuals. Tool B does not provide any explicit information regarding its support services or documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature ASSURE Wearable ECG ElucidVivo A.3
Name ASSURE Wearable ECG ElucidVivo A.3
Company Kestra Medical Technologies Elucid Bioimaging
Primary Function Non-therapeutic device for continuous heart rate monitoring and data collection for at-risk cardiac patients. AI-powered medical image analysis system for quantitative analysis of arterial plaque composition and stability from CT angiography.
Target Specialties Cardiology Cardiology, Radiology, Vascular Surgery
Key Technology/Method Wearable ECG device with SensorFit Garment, ASSURE Detection Algorithm with Quad Channel Processingu2122, and Adaptive Patient Intelligenceu2122. AI-powered quantitative analysis of arterial plaque from CT images, validated on ground-truth histology.
Specific Output/Analysis Continuous heart rate monitoring, automatic episode storage, alert-based notifications, physiologic trend data, Kestra CareStation remote patient data platform for clinician review. Quantification of Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications; visualization of lesion-level plaque composition; 3D visualization of highlighted vessels; derivation of fractional flow reserve (FFRct).

Videos

Demos, reviews, and walkthroughs featuring ASSURE Wearable ECG and ElucidVivo A.3.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The ASSURE Wearable ECG is a non-therapeutic device for continuous heart rate monitoring and data collection for at-risk cardiac patients, often following the use of a Wearable Cardioverter Defibrillator (WCD), to inform clinical management. ElucidVivo A.3 is an AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.
The ASSURE Wearable ECG analyzes continuous electrocardiogram (ECG) data, heart rate information, and automatically stored event data for low and high heart rates, as well as patient-triggered events. ElucidVivo A.3 analyzes CT angiography images to objectively quantify arterial plaque components such as Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications. It also derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.
The ASSURE Wearable ECG involves a wearable device for the patient, a mobile application, and a cloud-based remote patient data platform (Kestra CareStation) for clinician review, with data transmitted wirelessly. ElucidVivo A.3 is a software application, likely on-premise or cloud-based, designed to integrate with existing medical imaging systems such as PACS and EMR.
The ASSURE Wearable ECG is designed to support Cardiology. ElucidVivo A.3 is intended for use across Cardiology, Radiology, and Vascular Surgery specialties.
The ASSURE Wearable ECG provides continuous heart rate monitoring, automatic episode storage, alert-based notifications, and physiologic trend data for clinician review, utilizing algorithms to filter motion artifacts. ElucidVivo A.3 offers quantitative analysis of arterial plaque, objectively quantifying Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, along with 3D visualization of vessels and derivation of fractional flow reserve (FFRct).
The ASSURE Wearable ECG focuses on continuous monitoring for at-risk cardiac patients, particularly those transitioning from a WCD, to inform clinical management of various cardiac conditions and trends, including transient symptoms. ElucidVivo A.3 specifically addresses atherosclerosis patient stratification and optimizing treatment decisions by analyzing arterial plaque composition and stability from CT angiography, aiming to provide insights into the drivers of heart attack and stroke.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring ASSURE Wearable ECG or ElucidVivo A.3

Backers

Who funded each tool's parent company.

ASSURE Wearable ECG

AI Tool Finder
AI-powered search. Results may not be comprehensive.